{"acquisitions":[],"changes":[],"country":"US","description":"Sidewinder Therapeutics is a San Diego clinical-stage biotech developing precision bispecific antibody-drug conjugates for hard-to-treat solid tumors. It targets squamous-cell carcinomas of lung and head/neck and gastrointestinal cancers. The ADCs bind receptor co-complexes on tumor cells; a $137M Series B takes the lead to clinic in 2027.","domain":"sidewinder.bio","employees":null,"founded":2022,"fundingTotalQuarantined":false,"githubOrg":null,"githubStars":null,"industry":"unknown","industrySources":[],"investors":[],"lat":32.716692,"lng":-117.169295,"location":"San Diego CA","multiples":[],"name":"Sidewinder Therapeutics","people":[],"revenues":[],"rounds":[{"amountQuarantined":false,"amountUsd":137000000,"connectionsAmong":[],"currency":"USD","date":"2026-04-01","investments":[],"investors":[],"leadInvestor":null,"leadInvestors":[],"people":[],"slug":"sidewinder-bio-2026-04-01-series-b","source":{"fact":"round","publisher":"crunchbase","retrievedAt":"2026-05-07","status":"attributed","url":null},"status":"attributed","type":"series-b","url":null}],"slug":"sidewinder-bio","sources":[{"fact":"round","publisher":"crunchbase","retrievedAt":"2026-05-07","status":"attributed","url":null},{"fact":"existence","publisher":"sidewinder.bio","retrievedAt":"2026-05-07","status":"self-reported","url":"https://sidewinder.bio"},{"fact":"description","publisher":"sidewinder.bio","retrievedAt":"2026-05-07","status":"self-reported","url":"https://sidewinder.bio"}],"stage":"series-b+","stockCard":{"asOf":"2026-11-09","facts":[],"generatedAt":"2026-11-09","state":"insufficient-evidence","tldr":[]},"techStack":[],"totalRaisedUsd":200000000,"traction":[],"updatedAt":"2026-05-07","valuations":[]}